EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, HRMY: Harmony Biosciences Holdings Inc

05 Nov 25 15:59
LAST:

31.33

CHANGE:
 0.63		OPEN:
30.57		HIGH:
31.48		ASK:
0.00		VOLUME:
826.8K
CHG(%):
2.05		PREV:
30.72		LOW:
29.56		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
05 Nov 2530.3331.4829.5631.351.45M
04 Nov 2529.3130.8927.6630.721.74M
03 Nov 2528.5029.6028.4029.331.63M
31 Oct 2528.6929.0028.5028.57713.0K
30 Oct 2529.3229.5028.7428.90807.7K
29 Oct 2529.6029.7628.9129.32611.5K
28 Oct 2530.0030.0229.4629.64611.9K
27 Oct 2530.9030.9629.7230.11708.7K
24 Oct 2529.7330.3829.5730.25933.5K
23 Oct 2528.1229.9027.0229.602.15M

COMPANY PROFILE

Name:Harmony Biosciences Holdings Inc
About:Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Sector:Healthcare
Industry:Biotechnology
Address:630 West Germantown Pike, Plymouth Meeting, PA, United States, 19462
Website:https://www.harmonybiosciences.com
CUSIP:413197104
CIK:0001802665
ISIN:US4131971040
FIGI:BBG00WBPG4C2

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:9.22 
Forward P/E:8.76 
PEG Ratio:0.04 
Price to Sales:2.13 
Price to Book:2.13 
Profit Margin:0.23 
Operating Margin:0.24 
Return on Assets:0.14 
Return on Equity:0.28 
EPS Ratio:3.10 
Revenue:772.53M 
EBITDA:265.05M 
Shares:57.53M 
Market Cap:1.802B 

TECHNICAL INDICATORS

MA5:29.775.2%
MA10:29.785.2%
MA20:28.0611.6%
MA50:30.283.5%
MA100:32.473.7%
MA200:33.135.8%
STO9:95.53 
STO14:97.67 
RSI14:80.47 
MTM14:5.45
ROC14:0.21 
ATR:1.22 
Week High:31.480.5%
Week Low:27.6613.3%
Month High:31.480.5%
Month Low:25.525.8%
Year High:40.9330.6%
Year Low:25.5222.8%